Skip to main content

targeted cancer therapy Archives

Targeted cancer drug during pregnancy

Aug. 2, 2022—The targeted cancer therapy alectinib was safe as a treatment for lung cancer during two pregnancies in a patient with non-small cell lung cancer, according to a case report from Vanderbilt physicians.

Read more


Molecular testing across tumor types

Apr. 25, 2022—The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.

Read more


Melanoma treatment response

Feb. 24, 2022—Targeting the interaction between melanoma and immune cells could improve responses to targeted cancer therapies, Vanderbilt researchers found.

Read more


Treating metastatic prostate cancer

Jun. 22, 2021—An indirect comparative effectiveness study using published data suggests that the targeted therapy olaparib should be re-evaluated for treating metastatic prostate cancer.

Read more


Study reframes approach to targeted therapy resistance

Apr. 11, 2019—When a tumor mutates and develops resistance to a targeted therapy, researchers often focus on the acquisition of new mutations within the drug target as they seek an alternative treatment, but a team of Vanderbilt scientists has shown this may not be sufficient.

Read more


PET imaging to predict tumor response

Jun. 14, 2017—A PET probe that detects the amino acid glutamine predicts whether tumors respond to certain targeted therapies in preclinical animal models.

Read more


Drug combos for glioblastoma

May. 3, 2016—Vanderbilt researchers have discovered that activation of a certain signaling pathway protects brain cancers from targeted therapies, suggesting that using therapeutics that block both pathways may be a promising treatment.

Read more


IOM study calls for better evidence for biomarker tests

Mar. 10, 2016—Biomarker tests that help determine which patients may benefit from molecularly targeted therapies need better evidence and oversight to improve their effectiveness and availability, according to a study by the Institute of Medicine (IOM) of the National Academies of Sciences, Engineering, and Medicine.

Read more


Overcoming lung cancer drug resistance

Feb. 10, 2016—Vanderbilt investigators have discovered a way to overcome the resistance of some lung cancers to certain targeted therapies, which could lead to more effective treatments for lung cancer patients.

Read more


Limiting breast cancer metastasis

Aug. 28, 2014—Vanderbilt researchers have identified a new target for blocking breast cancer metastasis.

Read more


Drug discovery clues in network map

Aug. 5, 2014—Vanderbilt investigators have constructed a network map that could guide the development of new targeted cancer therapies.

Read more


New target for breast cancer therapy

Jul. 31, 2014—The protein MTBP is overexpressed in an aggressive type of breast cancer, and it regulates another protein implicated in many cancer types, suggesting that it may be a good target for new therapeutics.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more